Oncolytics Ev To Sales vs Operating Cash Flow Per Share Analysis

ONCY Stock

USD 0.73 0.06 7.59%

Oncolytics Biotech financial indicator trend analysis is much more than just breaking down Oncolytics Biotech prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Oncolytics Biotech is a good investment. Please check the relationship between Oncolytics Biotech Ev To Sales and its Operating Cash Flow Per Share accounts. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Oncolytics Biotech. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators.

For more information on how to buy Oncolytics Stock please use our How to Invest in Oncolytics Biotech guide.

Ev To Sales vs Operating Cash Flow Per Share

Ev To Sales vs Operating Cash Flow Per Share Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Oncolytics Biotech Ev To Sales account and Operating Cash Flow Per Share. At this time, the significance of the direction appears to have almost no relationship.

The correlation between Oncolytics Biotech's Ev To Sales and Operating Cash Flow Per Share is 0.1. Overlapping area represents the amount of variation of Ev To Sales that can explain the historical movement of Operating Cash Flow Per Share in the same time period over historical financial statements of Oncolytics Biotech, assuming nothing else is changed. The correlation between historical values of Oncolytics Biotech's Ev To Sales and Operating Cash Flow Per Share is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Ev To Sales of Oncolytics Biotech are associated (or correlated) with its Operating Cash Flow Per Share. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Operating Cash Flow Per Share has no effect on the direction of Ev To Sales i.e., Oncolytics Biotech's Ev To Sales and Operating Cash Flow Per Share go up and down completely randomly.

Correlation Coefficient

0.1

Relationship Direction	Positive
Relationship Strength	Insignificant

View All Relationships

Ev To Sales

The Enterprise Value to Sales ratio, a valuation metric used to compare the value of a company, including debt and excluding cash, to its sales revenue.

Operating Cash Flow Per Share

A measure of the cash generated from a company's normal business operations per share, indicating how much cash is generated from a company's business operations on a per-share basis.

Most indicators from Oncolytics Biotech's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Oncolytics Biotech current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Oncolytics Biotech. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators.

For more information on how to buy Oncolytics Stock please use our How to Invest in Oncolytics Biotech guide.At this time, Oncolytics Biotech's Selling General Administrative is fairly stable compared to the past year. Enterprise Value is likely to rise to about 118 M in 2025, whereas Tax Provision is likely to drop slightly above 84.1 K in 2025.

	2022	2023	2024	2025 (projected)
Interest Income	528K	1.2M	1.3M	1.4M
Net Interest Income	528K	1.2M	1.3M	1.4M

Interest Income Net Interest Income

Oncolytics Biotech fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Other Current Liab	Net Tangible Assets	Common Stock Total Equity	Short Term Investments	Common Stock	Property Plant Equipment	Non Currrent Assets Other
Total Assets		0.21	0.02	0.88	0.72	-0.85	-0.65	-0.12	0.83	-0.15	0.99	-0.19	0.73	0.52	0.67	0.68	0.4	0.53	1.0	0.2	0.71	0.48	0.27	0.69	0.72	0.49
Short Long Term Debt Total	0.21		0.03	-0.07	0.41	-0.08	-0.62	-0.61	0.12	0.0	0.11	0.36	0.49	0.75	0.56	0.57	0.57	0.51	0.21	0.25	0.52	0.59	0.2	0.53	0.55	0.15
Total Current Liabilities	0.02	0.03		-0.29	0.29	0.01	-0.16	0.25	-0.02	-0.39	-0.02	0.33	-0.08	0.08	0.17	0.22	0.64	0.33	0.04	0.77	-0.35	0.06	0.11	0.08	0.32	-0.05
Total Stockholder Equity	0.88	-0.07	-0.29		0.52	-0.8	-0.37	0.06	0.72	-0.05	0.92	-0.35	0.47	0.16	0.32	0.39	-0.05	0.15	0.88	-0.14	0.59	0.2	0.15	0.4	0.45	0.54
Property Plant And Equipment Net	0.72	0.41	0.29	0.52		-0.6	-0.77	-0.27	0.54	-0.23	0.68	0.03	0.54	0.57	0.6	0.76	0.6	0.57	0.73	0.36	0.58	0.65	0.36	0.65	0.93	0.49
Net Debt	-0.85	-0.08	0.01	-0.8	-0.6		0.47	0.05	-0.96	0.37	-0.87	0.27	-0.55	-0.35	-0.58	-0.5	-0.27	-0.43	-0.85	-0.15	-0.56	-0.34	-0.05	-0.54	-0.55	-0.21
Retained Earnings	-0.65	-0.62	-0.16	-0.37	-0.77	0.47		0.37	-0.51	0.36	-0.59	-0.09	-0.8	-0.81	-0.77	-0.98	-0.71	-0.68	-0.66	-0.22	-0.76	-0.92	-0.39	-0.94	-0.75	-0.22
Accounts Payable	-0.12	-0.61	0.25	0.06	-0.27	0.05	0.37		-0.12	-0.43	-0.03	-0.04	-0.5	-0.68	-0.59	-0.26	-0.37	-0.61	-0.09	-0.25	-0.53	-0.45	-0.36	-0.39	-0.29	0.08
Cash	0.83	0.12	-0.02	0.72	0.54	-0.96	-0.51	-0.12		-0.34	0.84	-0.29	0.69	0.45	0.71	0.54	0.35	0.56	0.82	0.15	0.65	0.44	0.01	0.66	0.51	0.13
Non Current Assets Total	-0.15	0.0	-0.39	-0.05	-0.23	0.37	0.36	-0.43	-0.34		-0.2	-0.13	0.01	0.01	-0.08	-0.4	-0.22	0.03	-0.19	-0.09	0.02	-0.31	0.14	-0.31	-0.15	0.29
Cash And Short Term Investments	0.99	0.11	-0.02	0.92	0.68	-0.87	-0.59	-0.03	0.84	-0.2		-0.31	0.66	0.41	0.58	0.62	0.3	0.44	0.99	0.13	0.66	0.42	0.23	0.63	0.67	0.47
Net Receivables	-0.19	0.36	0.33	-0.35	0.03	0.27	-0.09	-0.04	-0.29	-0.13	-0.31		-0.15	0.17	0.04	0.11	0.32	-0.01	-0.18	0.27	-0.14	0.08	-0.04	-0.02	0.04	-0.03
Common Stock Shares Outstanding	0.73	0.49	-0.08	0.47	0.54	-0.55	-0.8	-0.5	0.69	0.01	0.66	-0.15		0.84	0.92	0.79	0.61	0.83	0.7	0.14	0.9	0.78	0.26	0.92	0.6	0.22
Non Current Liabilities Total	0.52	0.75	0.08	0.16	0.57	-0.35	-0.81	-0.68	0.45	0.01	0.41	0.17	0.84		0.9	0.79	0.82	0.82	0.5	0.36	0.73	0.78	0.4	0.83	0.66	0.17
Other Current Assets	0.67	0.56	0.17	0.32	0.6	-0.58	-0.77	-0.59	0.71	-0.08	0.58	0.04	0.92	0.9		0.76	0.8	0.95	0.65	0.45	0.77	0.75	0.29	0.88	0.66	0.07
Other Stockholder Equity	0.68	0.57	0.22	0.39	0.76	-0.5	-0.98	-0.26	0.54	-0.4	0.62	0.11	0.79	0.79	0.76		0.73	0.67	0.69	0.25	0.73	0.86	0.28	0.93	0.74	0.28
Total Liab	0.4	0.57	0.64	-0.05	0.6	-0.27	-0.71	-0.37	0.35	-0.22	0.3	0.32	0.61	0.82	0.8	0.73		0.83	0.4	0.72	0.36	0.64	0.36	0.7	0.67	0.09
Property Plant And Equipment Gross	0.53	0.51	0.33	0.15	0.57	-0.43	-0.68	-0.61	0.56	0.03	0.44	-0.01	0.83	0.82	0.95	0.67	0.83		0.51	0.58	0.62	0.67	0.27	0.78	0.64	0.04
Total Current Assets	1.0	0.21	0.04	0.88	0.73	-0.85	-0.66	-0.09	0.82	-0.19	0.99	-0.18	0.7	0.5	0.65	0.69	0.4	0.51		0.2	0.69	0.48	0.27	0.68	0.73	0.48
Other Current Liab	0.2	0.25	0.77	-0.14	0.36	-0.15	-0.22	-0.25	0.15	-0.09	0.13	0.27	0.14	0.36	0.45	0.25	0.72	0.58	0.2		-0.09	0.05	0.29	0.18	0.41	-0.01
Net Tangible Assets	0.71	0.52	-0.35	0.59	0.58	-0.56	-0.76	-0.53	0.65	0.02	0.66	-0.14	0.9	0.73	0.77	0.73	0.36	0.62	0.69	-0.09		0.76	0.28	0.84	0.59	0.34
Common Stock Total Equity	0.48	0.59	0.06	0.2	0.65	-0.34	-0.92	-0.45	0.44	-0.31	0.42	0.08	0.78	0.78	0.75	0.86	0.64	0.67	0.48	0.05	0.76		0.34	0.92	0.61	0.06
Short Term Investments	0.27	0.2	0.11	0.15	0.36	-0.05	-0.39	-0.36	0.01	0.14	0.23	-0.04	0.26	0.4	0.29	0.28	0.36	0.27	0.27	0.29	0.28	0.34		0.28	0.35	0.18
Common Stock	0.69	0.53	0.08	0.4	0.65	-0.54	-0.94	-0.39	0.66	-0.31	0.63	-0.02	0.92	0.83	0.88	0.93	0.7	0.78	0.68	0.18	0.84	0.92	0.28		0.65	0.14
Property Plant Equipment	0.72	0.55	0.32	0.45	0.93	-0.55	-0.75	-0.29	0.51	-0.15	0.67	0.04	0.6	0.66	0.66	0.74	0.67	0.64	0.73	0.41	0.59	0.61	0.35	0.65		0.48
Non Currrent Assets Other	0.49	0.15	-0.05	0.54	0.49	-0.21	-0.22	0.08	0.13	0.29	0.47	-0.03	0.22	0.17	0.07	0.28	0.09	0.04	0.48	-0.01	0.34	0.06	0.18	0.14	0.48

Click cells to compare fundamentals

Oncolytics Biotech Account Relationship Matchups

Oncolytics Biotech fundamental ratios Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	34.3M	45.9M	37.3M	38.8M	44.6M	30.5M
Short Long Term Debt Total	402.1K	654.8K	373K	423K	486.5K	279.6K
Total Current Liabilities	2.7M	2.7M	3.9M	4.2M	4.9M	3.9M
Total Stockholder Equity	24.8M	36.1M	26.5M	27.6M	24.8M	17.8M
Property Plant And Equipment Net	609.1K	976.3K	652K	647K	582.3K	460.6K
Net Debt	(30.8M)	(40.6M)	(11.3M)	(34.5M)	(31.0M)	(29.5M)
Retained Earnings	(367.1M)	(393.4M)	(418.3M)	(446.0M)	(401.4M)	(381.3M)
Accounts Payable	1.8K	594K	2.3M	1.1M	1.2M	1.2M
Cash	31.2M	41.3M	11.7M	34.9M	40.1M	42.2M
Non Current Assets Total	609.1K	976.3K	1.7M	647K	582.3K	553.2K
Cash And Short Term Investments	31.2M	41.3M	32.1M	34.9M	40.1M	26.6M
Net Receivables	89.7K	866.1K	521K	15K	17.3K	16.4K
Common Stock Shares Outstanding	40.3M	53.5M	58.0M	67.6M	77.8M	81.7M
Liabilities And Stockholders Equity	34.3M	45.9M	37.3M	38.8M	44.6M	30.5M
Non Current Liabilities Total	6.9M	7.1M	6.9M	7.0M	8.1M	8.5M
Other Current Assets	2.4M	2.8M	1.7M	3.2M	3.7M	3.9M
Other Stockholder Equity	31.0M	37.8M	40.1M	42.1M	37.9M	38.1M
Total Liab	9.6M	9.8M	10.8M	11.3M	12.9M	13.6M
Property Plant And Equipment Gross	609.1K	976.3K	652K	1.3M	1.5M	1.6M
Total Current Assets	33.7M	44.9M	35.7M	38.2M	43.9M	28.0M
Accumulated Other Comprehensive Income	400.2K	387.7K	662K	544K	489.6K	465.1K
Other Current Liab	2.5M	1.8M	1.5M	3.0M	3.5M	1.9M
Net Tangible Assets	(107.9K)	24.8M	36.1M	26.5M	30.5M	32.0M
Short Term Investments	30.4M	1.4M	20.5M	3.4M	3.0M	2.9M
Short Term Debt	248.9K	294K	216K	133K	153.0K	127.3K
Common Stock	356.8M	391.3M	404.0M	430.9M	495.5M	520.3M
Property Plant Equipment	727.5K	609.1K	976.3K	652K	749.8K	377.8K
Capital Lease Obligations	402.1K	654.8K	373K	423K	486.5K	288.3K
Current Deferred Revenue	(3.2K)	(1.8K)	(594K)	(1.1M)	(973.8K)	(925.1K)
Net Invested Capital	24.8M	36.1M	26.5M	27.6M	31.7M	20.3M
Net Working Capital	31.0M	42.2M	31.7M	33.9M	39.0M	26.6M
Capital Stock	356.8M	391.3M	404.0M	430.9M	495.5M	399.6M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

F	Ford Motor
GM	General Motors
S	SentinelOne

Additional Tools for Oncolytics Stock Analysis

When running Oncolytics Biotech's price analysis, check to measure Oncolytics Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Oncolytics Biotech is operating at the current time. Most of Oncolytics Biotech's value examination focuses on studying past and present price action to predict the probability of Oncolytics Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Oncolytics Biotech's price. Additionally, you may evaluate how the addition of Oncolytics Biotech to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Oncolytics Ev To Sales vs Operating Cash Flow Per Share Analysis

Ev To Sales vs Operating Cash Flow Per Share

Ev To Sales vs Operating Cash Flow Per Share Correlation Analysis

Correlation Coefficient

Ev To Sales

Operating Cash Flow Per Share

Oncolytics Biotech fundamental ratios Correlations

Oncolytics Biotech Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Oncolytics Biotech fundamental ratios Accounts

Also Currently Popular

Additional Tools for Oncolytics Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Current Assets	+ 1.0	Total Assets
Cash And Short Term Investments	+ 0.99	Total Assets
Total Current Assets	+ 0.99	Cash And Short Term Investments
Property Plant And Equipment Gross	+ 0.95	Other Current Assets
Property Plant Equipment	+ 0.93	Property Plant And Equipment Net
Common Stock	+ 0.93	Other Stockholder Equity

Other Stockholder Equity	- 0.98	Retained Earnings
Cash	- 0.96	Net Debt
Common Stock	- 0.94	Retained Earnings
Common Stock Total Equity	- 0.92	Retained Earnings
Cash And Short Term Investments	- 0.87	Net Debt
Total Current Assets	- 0.85	Net Debt